161 related articles for article (PubMed ID: 35960849)
1. Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma.
Vanden Bempt M; Debackere K; Demeyer S; Van Thillo Q; Meeuws N; Prieto C; Provost S; Mentens N; Jacobs K; Gielen O; Nittner D; Ogawa S; Kataoka K; Graux C; Tousseyn T; Cools J; Dierickx D
Blood; 2022 Dec; 140(23):2463-2476. PubMed ID: 35960849
[TBL] [Abstract][Full Text] [Related]
2. MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.
Liu L; Xu F; Chang CK; He Q; Wu LY; Zhang Z; Li X
Cell Death Dis; 2017 Oct; 8(10):e3126. PubMed ID: 29022893
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
[TBL] [Abstract][Full Text] [Related]
4. EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation.
Wang L; Chen C; Song Z; Wang H; Ye M; Wang D; Kang W; Liu H; Qing G
Nat Commun; 2022 Jan; 13(1):12. PubMed ID: 35013218
[TBL] [Abstract][Full Text] [Related]
5. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
6. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
Leukemia; 2023 Oct; 37(10):1969-1981. PubMed ID: 37591943
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.
Zhang H; Lv H; Jia X; Hu G; Kong L; Zhang T; Li L; Pan Y; Zhai Q; Meng B; Wang X; Wang H; Wang X
Oncol Lett; 2019 Aug; 18(2):1415-1423. PubMed ID: 31423206
[TBL] [Abstract][Full Text] [Related]
8. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
9. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
Nat Med; 2016 Jun; 22(6):632-40. PubMed ID: 27135738
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.
Tian X; Pelton A; Shahsafaei A; Dorfman DM
Mod Pathol; 2016 Sep; 29(9):1050-7. PubMed ID: 27282353
[TBL] [Abstract][Full Text] [Related]
11. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.
Shi M; Shahsafaei A; Liu C; Yu H; Dorfman DM
Leuk Lymphoma; 2015 Jul; 56(7):2087-91. PubMed ID: 25263318
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
14. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
16.
Zimmerman MW; Liu Y; He S; Durbin AD; Abraham BJ; Easton J; Shao Y; Xu B; Zhu S; Zhang X; Li Z; Weichert-Leahey N; Young RA; Zhang J; Look AT
Cancer Discov; 2018 Mar; 8(3):320-335. PubMed ID: 29284669
[TBL] [Abstract][Full Text] [Related]
17. EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
Yan J; Ng SB; Tay JL; Lin B; Koh TL; Tan J; Selvarajan V; Liu SC; Bi C; Wang S; Choo SN; Shimizu N; Huang G; Yu Q; Chng WJ
Blood; 2013 May; 121(22):4512-20. PubMed ID: 23529930
[TBL] [Abstract][Full Text] [Related]
18. Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic Plasticity.
Chen NM; Neesse A; Dyck ML; Steuber B; Koenig AO; Lubeseder-Martellato C; Winter T; Forster T; Bohnenberger H; Kitz J; Reuter-Jessen K; Griesmann H; Gaedcke J; Grade M; Zhang JS; Tsai WC; Siveke J; Schildhaus HU; Ströbel P; Johnsen SA; Ellenrieder V; Hessmann E
Gastroenterology; 2017 May; 152(6):1507-1520.e15. PubMed ID: 28188746
[TBL] [Abstract][Full Text] [Related]
19. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
20. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
